BusinessRapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for VaccinesBy Nasdaq OMXOct 23, 2017, 11:00 AM UTC
BusinessSummit Awarded BARDA Contract Worth Up to $62 Million to Support the Development of Ridinilazole for the Treatment of C. difficile InfectionBy Nasdaq OMXSep 11, 2017, 11:00 AM UTC
BusinessCempra Authorized to Receive Funds From BARDA for a Phase 2/3 Clinical Trial of Solithromycin in Pediatric PatientsBy Nasdaq OMXMar 7, 2016, 12:00 PM UTC
